Bardet–Biedl Syndrome Treatment
Feb 13, 2026
The Next Frontier in Bardet–Biedl Syndrome Treatment: Gene Therapy and Beyond
Summary Bardet–Biedl syndrome (BBS) is a rare, genetically heterogeneous disorder that affects more than 5,000 individuals in the United States. A major therapeutic milestone was the approval of IMCIVREE (setmelanotide), the first targeted MC4R agonist therapy addressing BBS-related obesity. Gene th...
Read More...
-Agonist.png "Toll-like Receptors Agonist")
